Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 1
2015 1
2018 1
2020 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
Cázares-Cortazar A, Uribe-Noguez LA, Mata-Marín JA, Gaytán-Martínez J, de la Luz Martínez-Rodríguez M, Villavicencio-Ferrel PE, Chapararro-Sánchez A, Mauss S, Ocaña-Mondragón A. Cázares-Cortazar A, et al. Among authors: mata marin ja. Arch Virol. 2020 Dec;165(12):2759-2766. doi: 10.1007/s00705-020-04797-y. Epub 2020 Sep 3. Arch Virol. 2020. PMID: 32885325
The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. ...
The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or …
Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.
Mata-Marín JA, Mata-Marín LA, Arroyo-Anduiza CI, Huerta-García G, Sandoval-Ramirez JL, Manjarrez-Tellez B, Gaytán-Martínez JE. Mata-Marín JA, et al. Hepatogastroenterology. 2014 Jul-Aug;61(133):1187-91. Hepatogastroenterology. 2014. PMID: 25436280 Clinical Trial.
The aim of the study was to examine the effectiveness of intensification with pegylated interferon (PEG-IFN) alfa-2a or alfa-2b in HBV/HIV-coinfected patients treated with a tenofovir/emtricitabine (TDF/FTC) backbone in an HIV clinic in Mexico City. ...
The aim of the study was to examine the effectiveness of intensification with pegylated interferon (PEG-IFN) alfa-2a or alfa-2 …
APRI as a predictor of early viral response in chronic hepatitis C patients.
Mata-Marín JA, Fuentes-Allen JL, Gaytán-Martínez J, Manjarrez-Téllez B, Chaparro-Sánchez A, Arroyo-Anduiza CI. Mata-Marín JA, et al. World J Gastroenterol. 2009 Oct 21;15(39):4923-7. doi: 10.3748/wjg.15.4923. World J Gastroenterol. 2009. PMID: 19842223 Free PMC article.
We enrolled chronic hepatitis C naive patients who were evaluated to start therapy with PEGylated interferon alpha-2b (1.5 mug/kg per week) and ribavirin (> 75 kg: 1200 mg and < 75 kg: 1000 mg). ...
We enrolled chronic hepatitis C naive patients who were evaluated to start therapy with PEGylated interferon alpha-2b (1.5 mug …
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Cázares-Cortázar A, Ribas-Aparicio RM, Gómez-Torres ME, Gaytán-Martínez J, Martínez-Rodríguez ML. Uribe-Noguez LA, et al. Among authors: mata marin ja. J Infect Chemother. 2018 Nov;24(11):928-931. doi: 10.1016/j.jiac.2018.04.001. Epub 2018 Oct 15. J Infect Chemother. 2018. PMID: 29773440
Therapeutic failure occurred with initial treatment with PEGylated interferon-alpha2b and ribavirin, but the use of sofosbuvir and daclatasvir on a re-treatment regimen after reclassification of the infecting virus resulted in a sustained virologic response. ...
Therapeutic failure occurred with initial treatment with PEGylated interferon-alpha2b and ribavirin, but the use of sofosbuvir …
Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Sandoval-Ramirez JL, Mata-Marín JA, Huerta García G, Gaytán-Martínez JE. Sandoval-Ramirez JL, et al. Among authors: mata marin ja. J Infect Dev Ctries. 2015 Mar 15;9(3):267-73. doi: 10.3855/jidc.5284. J Infect Dev Ctries. 2015. PMID: 25771464 Free article.
Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in low-income countries, including Mexico. ...CONCLUSIONS: Similar SVR rates and frequencies of adverse events were observed. Either t …
Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of …